Gene Cloning Services Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Service Type (Gene Synthesis Service, Molecular Biology Service, Custom Cloning Service, Others), By Gene Type (Stranded Gene, Complex Gene, Others), By Application (Gene Synthesis, Gene Expression, Gene Therapy, Vaccine Research, Others), By End User (Pharmaceutical & Biotechnology Companies, Clinical Laboratories, Others), and By Region 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 3.59 Billion
CAGR (2026-2031)	15.54%
Fastest Growing Segment	Gene Synthesis
Largest Market	North America
Market Size (2031)	USD 8.54 Billion

Market Overview

The Global Gene Cloning Services Market will grow from USD 3.59 Billion in 2025 to USD 8.54 Billion by 2031 at a 15.54% CAGR. Gene cloning services encompass the specialized laboratory processes used to assemble recombinant DNA molecules and replicate them within host organisms to generate identical copies of specific genetic sequences. These services, which include gene synthesis, plasmid design, and mutagenesis, are essential for downstream therapeutic and research applications. The primary drivers supporting market growth are the escalating demand for personalized medicine and the robust expansion of the biotechnology sector, particularly in biologics development. Furthermore, the rising prevalence of chronic and genetic diseases necessitates accelerated research workflows, thereby reinforcing the fundamental requirement for these precision cloning technologies.

However, a significant challenge impeding market expansion is the high operational cost and technical complexity associated with advanced cloning procedures, which can create barriers to entry for smaller research institutions. This high volume of necessary research activity is reflected in recent industry data. According to the American Society of Gene & Cell Therapy, in 2025, there were more than 3,200 gene, cell, and RNA therapy trials underway globally, underscoring the critical reliance on cloning services to sustain such a vast therapeutic pipeline.

Key Market Drivers

The increasing demand for gene and cell therapies serves as a primary catalyst for the Global Gene Cloning Services Market. As pharmaceutical pipelines shift toward biologics, the necessity for precision cloning to generate viral vectors, recombinant plasmids, and modified DNA sequences has intensified. These services are fundamental for constructing the complex genetic payloads required for treatments targeting rare genetic disorders and oncology. The regulatory success of these advanced treatments further fuels this demand, creating a continuous need for high-fidelity cloning during both the development and manufacturing phases. According to the Alliance for Regenerative Medicine, January 2024, in the 'State of the Industry' presentation, regulatory bodies in the United States and European Union approved a record five gene therapies for rare diseases in 2023, signaling a maturing market that relies heavily on scalable cloning workflows.

Concurrently, a surge in government funding and private investment for life sciences research is accelerating the adoption of outsourced cloning models. Financial injections enable biotechnology firms and academic centers to bypass the capital-intensive setup of in-house cloning facilities by utilizing specialized service providers. This trend is evident in the financial commitments of major industry players toward discovery and pre-clinical work. According to PhRMA, in their '2024 Membership Survey' released in August 2024, member companies invested USD 103.5 billion in research and development during 2023, a significant portion of which supports discovery phases where cloning is critical. This robust funding environment translates directly into service provider growth; according to Twist Bioscience, November 2024, in the 'Fiscal 2024 Financial Results', the company reported total revenue of USD 313 million, reflecting the expanding reliance on synthetic biology and cloning services across the sector.

Download Free Sample Report

Key Market Challenges

The high operational cost and technical complexity associated with advanced gene cloning procedures constitute a substantial impediment to the growth of the Global Gene Cloning Services Market. These intricate techniques require expensive instrumentation, specialized reagents, and highly skilled personnel, creating significant financial barriers for smaller research institutions and emerging biotechnology firms. Consequently, these entities often face difficulties in allocating sufficient budgets for outsourcing these critical services, limiting the overall customer base and slowing the adoption rate of precision cloning technologies across the broader industry.

This financial strain is evident in recent investment trends affecting the sector's primary clientele. According to the Biotechnology Innovation Organization, in 2025, biotech startup funding dropped significantly from 2.6 billion dollars in the first quarter to 900 million dollars in the second quarter. This sharp decline in available capital directly forces early-stage companies to scale back research and development activities. As a result, the demand for external gene cloning services from this vital segment diminishes, directly hampering the market's potential for rapid expansion.

Key Market Trends

The Integration of Artificial Intelligence for Sequence Optimization is fundamentally reshaping gene cloning by enhancing the predictive design of complex genetic constructs. Advanced algorithms are now routinely employed to analyze vast datasets, allowing service providers to optimize codon usage, predict secondary structures, and eliminate instability regions before synthesis begins. This digital shift minimizes experimental failure rates and accelerates the design-to-product timeline for custom vectors. The operational impact of this technological adoption is substantial within the life sciences R&D sector. According to the Pistoia Alliance, September 2025, in the '2025 Lab of the Future Survey', 77% of life sciences laboratories expect to utilize Artificial Intelligence technologies within the next two years, reflecting a critical industry-wide pivot toward computational precision in genetic engineering.

Simultaneously, the Deployment of Automated High-Throughput Cloning Platforms is revolutionizing service scalability, allowing providers to process massive libraries with unprecedented speed. By replacing manual pipetting with robotic liquid handling systems, contract research organizations can execute thousands of simultaneous cloning reactions, significantly reducing turnaround times for large-scale plasmid preparation and mutant library construction. This operational efficiency drives commercial success and accommodates the surging volume of synthetic biology projects. This trend is exemplified by major industry players expanding their automated capabilities; according to GenScript Biotech Corporation, March 2025, in the 'FY 2024 Results', the company reported revenue from continuing operations of USD 594.5 million, highlighting the robust financial performance underpinning the expansion of their industrial-scale cloning and synthesis services.

Segmental Insights

The Gene Synthesis segment represents the fastest-growing area in the Global Gene Cloning Services Market. This expansion is primarily driven by the increasing demand for custom DNA sequences in synthetic biology and genomic research. The method offers distinct operational advantages over traditional cloning by eliminating the need for physical DNA templates, thereby streamlining the workflow for researchers. Additionally, the rigorous quality requirements for gene therapy products, monitored by regulatory bodies like the US FDA, necessitate the high precision that synthesis provides. Consequently, pharmaceutical institutions are prioritizing these services to accelerate the development of therapeutic treatments and vaccines.

Regional Insights

North America holds a dominant position in the global gene cloning services market due to substantial investments in biotechnology research and development. The region benefits from a high concentration of established pharmaceutical companies and academic research centers that require extensive cloning services for drug discovery and genomic studies. Furthermore, consistent funding from federal organizations, such as the National Institutes of Health, supports continuous advancement in life sciences. The presence of a clear regulatory framework provided by the U.S. Food and Drug Administration also facilitates the commercialization of biopharmaceuticals, thereby sustaining regional market leadership.

Recent Developments

• In August 2024, Twist Bioscience Corporation expanded its synthetic DNA product line by launching gene fragments with lengths extended up to 5.0 kb. This development provides researchers with longer, double-stranded DNA constructs that are compatible with a wide range of downstream cloning workflows, including Gateway and Golden Gate assembly. The CEO of Twist Bioscience noted that this product evolution eliminates the need for scientists to stitch together smaller fragments, thereby streamlining the construction of complex genes. The launch reinforces the company’s role in the market by offering scalable and precise tools essential for antibody discovery and functional genomics.
• In July 2024, Ansa Biotechnologies launched its inaugural commercial service providing clonal DNA constructs synthesized via a proprietary enzymatic platform. This new offering allows for the rapid production of complex sequences up to 7.5 kb, including those with difficult features like high GC content that often challenge traditional chemical synthesis methods. The CEO of Ansa Biotechnologies highlighted that this capability resolves longstanding bottlenecks in the supply of high-fidelity genetic material. By enabling the direct delivery of sequence-perfect DNA, the company aims to support critical applications in synthetic biology, such as metabolic engineering and protein design, without the limitations of conventional cloning.
• In June 2024, GenScript Biotech Corporation introduced the FLASH Gene service, a new sequence-to-plasmid synthesis offering designed to significantly reduce turnaround times for researchers. This service utilizes an optimized production platform to deliver custom plasmid constructs in as few as four business days, addressing the industry's demand for speed in antibody discovery and gene therapy development. The President of the Life Science Group at GenScript emphasized that this launch combines gene synthesis and cloning into a streamlined, flat-rate solution. The initiative reflects the company's commitment to enhancing the efficiency of genetic research and expanding its global cloning services capabilities.
• In January 2024, Elegen announced a strategic collaboration and licensing agreement with GSK to utilize its proprietary cell-free DNA manufacturing technology for the development of vaccines and medicines. This partnership enables the pharmaceutical company to leverage rapid, cell-free production methods that bypass the time-consuming steps of traditional cell-based cloning, such as plasmid linearization and purification. Under the agreement, Elegen is eligible to receive up to $35 million in near-term fees and development support, in addition to potential equity investment. The collaboration aims to accelerate the supply of high-complexity synthetic DNA for next-generation genetic medicines.

Key Market Players

• Thermo Fisher Scientific, Inc
• Eurofins Scientific SE
• GenScript Biotech Corp
• Merck KGaA
• Takara Bio Inc
• Charles River Laboratories International, Inc
• Sartorius AG
• Cellecta, Inc
• Creative Biogene, Inc
• Biocompare, Inc

By Service Type	By Gene Type	By Application	By End User	By Region
Gene Synthesis Service Molecular Biology Service Custom Cloning Service Others	Stranded Gene Complex Gene Others	Gene Synthesis Gene Expression Gene Therapy Vaccine Research Others	Pharmaceutical & Biotechnology Companies Clinical Laboratories Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Gene Cloning Services Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Gene Cloning Services Market, By Service Type:

• Gene Synthesis Service
• Molecular Biology Service
• Custom Cloning Service
• Others

• Gene Cloning Services Market, By Gene Type:

• Stranded Gene
• Complex Gene
• Others

• Gene Cloning Services Market, By Application:

• Gene Synthesis
• Gene Expression
• Gene Therapy
• Vaccine Research
• Others

• Gene Cloning Services Market, By End User:

• Pharmaceutical & Biotechnology Companies
• Clinical Laboratories
• Others

• Gene Cloning Services Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE